TREACE MEDICAL CONCEPTS, INC.·4

May 19, 9:00 PM ET

HAMILTON LAWRENCE W 4

Research Summary

AI-generated summary

Updated

Treace Medical (TMCI) Director Lawrence W. Hamilton Receives 30,000 RSUs

What Happened Lawrence W. Hamilton, a director of Treace Medical Concepts, Inc. (TMCI), was granted 30,000 restricted stock units (RSUs) on May 19, 2026. The award was recorded as an acquisition at $0.00 per share (no cash paid). The RSUs convert to one share of TMCI common stock each upon vesting.

Key Details

  • Transaction date: 2026-05-19; Grant/Award (Code A); 30,000 RSUs; reported acquisition price $0.00.
  • Vesting: 100% vesting on the earlier of (a) May 19, 2027 or (b) the date of the 2027 annual meeting, subject to continued service.
  • Deferral: Reporting person voluntarily elected to defer receipt of shares issuable on settlement until the earlier of a change in control or the Reporting Person’s separation of service.
  • Footnotes: F1 describes RSU mechanics and deferral; F2 confirms the grant size (30,000 RSUs).
  • Shares owned after transaction: not specified in this filing.
  • Filing timeliness: Reported on 2026-05-19 (same day as transaction), so not flagged late.

Context RSU grants are compensation, not open-market purchases or sales. They represent a promise to receive shares in the future if vesting conditions and service requirements are met; because Hamilton elected to defer settlement, the shares may not be issued until a change in control or his separation from service. Such awards are routine for directors and do not, by themselves, indicate a buy or sell signal.